<International Circulation>: There is a decline in the use of aspirin for treatment of thrombosis and atrial fibrillation. Does this imply that oral anti-coagulants should be used as a replacement for those on aspirin?
　　《国际循环》:在治疗血栓形成和房颤的过程中，阿司匹林的使用量正在下降。这是否意味着在治疗时应该用口服抗凝剂代替阿斯匹林?
　　Professor Vardas: Indeed in our guidelines， published just recently， we have recognized some groups of patients of AF on the basis of CHA2DS2-VASc score. In these guidelines it is indicated that patients with score of one， in other words， without any risk factors for stroke， no treatment is needed， not even aspirin. For those patients with a score of 2 or more a pure， real， anticoagulant (AC) treatment is indicated as a class I recommendation. If somebody is with one point， according the CHA2DS2-VASc score， then either anti-platelet therapy， a combination of aspirin and clopidogrel， or anticoagulant treatment is indicated. It is true that role of aspirin has been reduced in our guidelines. Instead， if we decide to treat the patients a real anticoagulant treatment is needed.
　　Vardas教授: 实际上在最近我们发布了关于治疗心颤的指南，我们已经公认可以在CHA2DS2-VASc评分系统的基础上将心颤的患者进行分类。在这些指导方针中表明得分为1的患者， 换句话说， 也就是没有任何卒中的危险的病人，是没有必要进行治疗的，也不需要用阿斯匹林。对那些得分是2或更高的患者，我建议可以进行单纯的抗凝治疗(AC)。根据CHA2DS2-VASc评分系统， 如果病人得分是1分，治疗方法是明确的，要么进行抗血小板治疗， 即在阿司匹林治疗基础上加入氯吡格雷， 要么进行抗凝治疗。根据我们的指南，表明阿司匹林在治疗过程中的应用已经减少。然而， 如果我们决定治疗病人，那么抗凝治疗的却是必要的。